On September 8, 2026, electroCore appointed Joshua Lev and Michael Fox as Co-Chief Executive Officers. Mr. Lev continues as CFO while Mr. Fox remains COO; both were elected to the Board, increasing its size from six to eight members. Their compensation was amended with base salaries raised to $540,000 each and target bonuses set at 50% of salary, accompanied by grants of 55,000 RSUs per executive. The company also adopted an Amended and Restated Executive Severance Policy and updated Bylaws to comply with SEC universal proxy rules and authorize the co-CEO structure. At its Annual Meeting on September 8, 2026, shareholders elected three directors, ratified CBIZ CPAs as auditors, and approved executive compensation via non-binding advisory votes. electroCore is a bioelectronic medicine company that develops non-invasive vagus nerve stimulation technologies for chronic pain and wellness.

electroCore reported second quarter 2026 net sales of $9.5 million, a 28% increase from $7.4 million in the prior year period. The company posted a GAAP net loss of $3.1 million, down from $3.7 million, with an adjusted EBITDA net loss of $1.8 million, representing a 26% improvement. Revenue growth was driven by U.S. prescription sales to the Department of Veterans Affairs and direct-to-consumer Truvaga channels. The company raised its full-year 2026 revenue guidance to greater than 30% year-over-year growth and expects to achieve positive adjusted EBITDA in the third quarter of 2027. electroCore operates in the bioelectronic medicine industry, developing non-invasive devices for headache treatment and general wellness.